Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.48 USD
+0.08 (0.85%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $9.49 +0.01 (0.11%) 7:58 PM ET
1-Strong Buy of 5 1
A Value A Growth F Momentum A VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
03/05/2025
Time: -- |
12/2024 | $-0.07 | 0.00% |
Earnings Summary
For their last quarter, Emergent Biosolutions (EBS) reported earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This reflects a positive earnings surprise of 179.59%. Look out for EBS's next earnings release expected on March 05, 2025. For the next earning release, we expect the company to report earnings of -$0.07 per share, reflecting a year-over-year increase of 90.91%.
Earnings History
Price & Consensus
Zacks News for EBS
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates
Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades
EBS FAQs
Emergent Biosolutions Inc. (EBS) has announced they will report their next quarter earnings on March 05, 2025. For the next earning release, we expect the company to report earnings of $-0.07 per share, reflecting a year-over-year increase of 90.91%.
Emergent Biosolutions Inc. has announced they will report their previous quarter earnings after the close of the market on March 05, 2025.
The Zacks Consensus Estimate for Emergent Biosolutions Inc. (EBS) for the quarter ending December 2024 is $-0.07 a share. We expect Emergent Biosolutions Inc. (EBS) to report earnings in line with the consensus estimate of $-0.07 per share
In the earnings report for the quarter ending in June 2024, Emergent Biosolutions Inc. (EBS) announced earnings of $-2.32 per share versus the Zacks Consensus Estimate of $-0.97 per share, representing a surprise of 139.18%.